期刊文献+

FISH与痰脱落细胞学在肺癌检测中的对比研究 被引量:1

Comparison between FISH and cytology of sputum samples in detection of lung cancer
下载PDF
导出
摘要 目的探讨荧光原位杂交技术(fluorescence in situ hybridization,FISH)检测痰液中脱落细胞进行肺癌诊断的可行性,并与痰脱落细胞学比较。方法选用3、7、17号染色体着丝粒探针,p16、p53探针和痰脱落细胞学技术,分别检测40例疑似肺癌患者的痰液,同期行痰脱落细胞学检查。20例健康人痰液标本,用于建立FISH阈值,作为阳性判断标准。结果 FISH和细胞学检查的敏感度分别为80.6%和22.6%,特异性分别为77.8%和100.0%,诊断符合率为80.0%和40.0%。两种方法在敏感度和诊断符合率上差异具有统计学意义(P<0.05),而特异性差异无统计学意义(P>0.05)。结论在肺癌诊断中FISH较常规细胞学具有更高的敏感度和诊断符合率,FISH技术能明显改进肺癌的诊断,可以作为肺癌诊断方法的补充。 Objective To evaluate the application of fluorescence in situ hybridization (FISH) assay in sputum for detection of lung cancer and to compare the results with sputum cytology test. Methods Sputum samples from 40 patients with suspected lung cancer were collected for cytology and FISH analysis. FISH was petformed using 3,7,17 and p16, p53 of chromosome-specific probes to examine chromosome aberration of exfoliated cells. FISH abnormality threshold was determined by evaluating the sputum specimen from 20 normal subjects. Results The sensitivity for lung cancer of FISH and cytology in sputum was 80.6% and 22.6%, respectively; specificity was 77.8% and 100.0% ; diagnostic concordance rate was 80.0% and 40.0%, respectively. Significant difference was found in specificity and diagnostic concordance rate between two methods ( P 〈 0.05 ). Conclusion The sensitivity and efficiency of FISH in detection of lung cancer are superior to those of cytology, and FISH in sputum samples can be a supplementary method for diagnosis of lung cancer.
出处 《实用肿瘤杂志》 CAS 2013年第2期197-199,共3页 Journal of Practical Oncology
基金 教育厅青年教师科研培养基金(XJEDU2009S54)
关键词 肺肿瘤 诊断 肺肿瘤 病理学 细胞学 DNA探针 原位杂交 荧光 染色体 细胞诊断学 对比研究 lung neoplasms/diagnosis lung neoplasms/pathology sputum/cytology DNA probes in situ hybridization, fluorescence chromosomes, human cytodiagnosis comparative study
  • 相关文献

参考文献7

  • 1Varella-Garcia M. Molecular cytogenetics in solid tumors Laboratorial tool for diagnosis, prognosis and therapy [J] Oncologist ,2003,8 ( 1 ) :45 - 58.
  • 2王巍,林耀东,陈泽程,徐绮华,张华,冼海兵,邓燕明.定量检测血清p53抗体预测晚期非小细胞肺癌预后[J].实用肿瘤杂志,2011,26(1):46-49. 被引量:16
  • 3Voss JS, Kipp BR, Halling KC, et al. Fluorescence in situ hybridization testing algorithm improves lung cancer detection in bronchial brushing specimens [J]. Am J Respir Crit Care Med,2010,181 (5) :478 -485.
  • 4Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) [J]. Chest,2007,132 (3 Suppl) :131S - 148S.
  • 5Miller YE, Prindiville S. Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality [ J ]. J Thorae 0ncol,2006,1 (4) :302 - 307.
  • 6Bubendorf L, Muller P, Joos L, et al. Multitarget FISH analysis in the diagnosis of lung cancer [ J ]. Am J Clin Pathol,2005,123 (4) :516 - 523.
  • 7贾东辉,张智慧,刘树范,程书钧.荧光原位杂交技术在肺癌痰细胞学诊断中的应用[J].中华肿瘤杂志,2000,22(6):477-479. 被引量:10

二级参考文献11

  • 1刘智鑫,刘国津.人非小细胞肺癌细胞药物敏感性检测及其与耐药因子p53抗体和GST-π表达的关系[J].吉林大学学报(医学版),2005,31(5):795-798. 被引量:9
  • 2张向群,王毓洲,张沪生.血清p53抗体与肺癌生物学行为和化疗疗效的关系[J].癌症进展,2006,4(6):550-553. 被引量:4
  • 3Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [J]. N Engl J Med, 2002, 346(2) :92 -98.
  • 4Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-smaU cell lung cancer (INTEREST): a randomised phase Ⅲ trial [J]. Lancet, 2008,372(9652) : 1809 - 1818.
  • 5Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer [ J ]. J Clin Oncol, 2007,25 ( 33 ) :5240 - 5247.
  • 6Shih CM, Chen K, Wang YC, et al. Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance [ J ]. Cancer Detect Prey, 2007, 31 ( 5 ) :366 - 370.
  • 7Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer [ J ]. J Clin Oncol,2008,26(21 ) :3543 -3551.
  • 8Sandler A, Gray R, Perry MC, et al. Paclitaxel- carboplatin alone or with bevacizumab for non-small cell lung cancer [ J ]. N Engl J Med, 2006,355 (24): 2542 - 2550.
  • 9Cajulis R S,Diagn Cytopathol,1997年,16卷,331页
  • 10韩毅,许绍发.血清p53抗体与肺癌的研究进展[J].中国肺癌杂志,2003,6(5):406-408. 被引量:3

共引文献24

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部